CHARLES WILLITS: Open Payments
NPI 1154065134 · KANSAS CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$652 in 30 payments from 11 companies in 2025. Trend: 2023 $116 · 2024 $456 · 2025 $652
Food & beverage: $652
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 8 | $154 |
| AstraZeneca Pharmaceuticals LP | 3 | $149 |
| PFIZER INC. | 4 | $64 |
| ABBVIE INC. | 3 | $61 |
| Novo Nordisk Inc | 3 | $56 |
| Sumitomo Pharma America, Inc. | 2 | $42 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $39 |
| Viatris Specialty LLC | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| SHIELD THERAPEUTICS INC | 1 | $20 |
Products named: FARXIGA, OTEZLA, NURTEC ODT, VRAYLAR, GEMTESA, CAPLYTA, Ozempic, AIRSUPRA.
Industry payments across MO — which companies pay providers there.
